石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

开市前 12-01 09:01:55

10.200

+0.210

+2.10%

最高10.200	最低10.200	成交量7.80万
今开10.200	昨收9.990	日振幅0.00%
总市值1,217亿	流通市值1,217亿	总股本119.33亿
成交额77.92万	换手率0.00%	流通股本119.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":10.2,"timestamp":1669856490065,"preClose":9.99,"halted":0,"volume":78000,"delay":0,"floatShares":11933219732,"shares":11933219732,"eps":0.520274,"marketStatus":"开市前","marketStatusCode":1,"change":0.21,"latestTime":"12-01 09:01:55","open":10.2,"high":10.2,"low":10.2,"amount":779220,"amplitude":0,"askPrice":10.2,"askSize":294000,"bidPrice":10.2,"bidSize":240000,"shortable":3,"etf":0,"ttmEps":0.5338279457055932,"exchange":"SEHK","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1669858200000},"adr":0,"listingDate":772128000000,"adjPreClose":9.99,"dividendRate":0.02575,"volumeRatio":0,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK"},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2288485136","title":"【券商聚焦】中泰国际上调石药集团(01093)目标价7.5%至11.82港元 指其首三季业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2288485136","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2288485136?lang=zh_CN&edition=full","pubTime":"2022-12-01 08:36","pubTimestamp":1669854983,"startTime":"0","endTime":"0","summary":"中泰国际发研报指，石药集团前三季度收入同比增加13.8%至约235.0亿元人民币（下同），股东净利润同比增长3.1%至44.7亿元，总体看收入与股东净利润略超预期。根据调整后DCF模型，该行将目标价从11.00港元上调7.5%至11.82港元，较目前股价有20.8%上涨空间，维持“买入”评级。根据2022年国家医保目录简易续约原则，该行认为恩必普在2022年版国家医保目录中的降价幅度将有限，预计恩必普2021-24E收入CAGR为10.0%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=8af72d495e43cb4156a51ec669afeacc","is_publish_highlight":false},{"id":"2287658426","title":"【券商聚焦】中信证券维持石药集团(01093)“买入”评级 指mRNA新冠疫苗望近期获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2287658426","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2287658426?lang=zh_CN&edition=full","pubTime":"2022-11-30 14:14","pubTimestamp":1669788873,"startTime":"0","endTime":"0","summary":"中信证券发布研究报告指出，石药集团2022年前三季度业绩稳定增长，实现收入、股东应占基本溢利、股东应占溢利分别为234.96、46.24、44.68，同比增长13.8%、14.5%、3.1%，总体整体业绩符合预期。该行指出，公司新冠mRNA疫苗多项临床研究报告已向CDE提交，两款新冠小分子药物展开布局。同时公司也在一些海外国家组织开展新冠mRNA疫苗的临床研究，短期内IND有望获批。公司研发成果显著，未来5年内30余款新品有望上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=6ce65f5297c6cc638b5a170373f77d28","is_publish_highlight":false},{"id":"2287741680","title":"港股公告掘金 | 这家医药公司开发的抗体药物偶联物 试验性新药申请获FDA批准!创新管线与技术平台迭出 今年有多款创新药上市或待上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2287741680","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2287741680?lang=zh_CN&edition=full","pubTime":"2022-11-30 08:25","pubTimestamp":1669767952,"startTime":"0","endTime":"0","summary":"石药集团：开发的抗体药物偶联物CPO204的试验性新药申请获FDA批准石药集团发布公告称，集团开发的抗体药物偶联物 CPO204的试验性新药申请已获得美国食品药品监督管理局批准，在美国开展1期、剂量递增及剂量扩展研究以评估该产品针对局部晚期或转移性泌尿道上皮癌患者的安全性、耐受性、药代动力学特性及初步疗效。预计首款mRNA新冠疫苗有望在2023年数据读出，siRNA、mRNA 及细胞治疗技术平台将陆续有产品进入IND阶段。本次项目为公司首个菲律宾项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/839389.html","is_publish_highlight":false},{"id":"2287550904","title":"格隆汇公告精选(港股)︱哔哩哔哩第三季度营收58亿元同比增长11%；汇丰控股拟出售旗下加拿大银行业务予加拿大皇家银行","url":"https://stock-news.laohu8.com/highlight/detail?id=2287550904","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2287550904?lang=zh_CN&edition=full","pubTime":"2022-11-29 23:46","pubTimestamp":1669736767,"startTime":"0","endTime":"0","summary":"阿里影业(01060.HK)公布中期业绩：营收增35%至18.29亿元，经调整EBITA扭亏为盈；宝尊电商-SW(09991.HK)第三季度GMV增加15.9%达186.32亿元 正朝着全渠道商业运营商的目标加速迈进","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/108.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/108.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.gelonghui.com/p/565747","is_publish_highlight":false},{"id":"2287578915","title":"【港股通】石药集团(01093)：抗体药物偶联物CPO204获美国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2287578915","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2287578915?lang=zh_CN&edition=full","pubTime":"2022-11-29 17:28","pubTimestamp":1669714083,"startTime":"0","endTime":"0","summary":"石药集团(01093)宣布，公司开发的抗体药物偶联物(Antibody-Drug Conjugate) CPO204的试验性新药申请(IND)已获得美国食品药品监督管理局（FDA）批准，在美国开展1期、剂量递增及剂量扩展研究以评估该产品针对局部晚期或转移性泌尿道上皮癌患者的安全性、耐受性、药代动力学特性及初步疗效。CPO204是一款单克隆抗体药物偶联物，可与肿瘤表面的特异性受体结合，通过内吞作用进入细胞，释放毒素，达到杀伤肿瘤细胞的作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=c383951077d52da3973df6978a24f665","is_publish_highlight":false},{"id":"2287052007","title":"石药集团(01093.HK)抗肿瘤药物获美国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2287052007","media":"AAFN","top":-1,"share":"https://www.laohu8.com/m/news/2287052007?lang=zh_CN&edition=full","pubTime":"2022-11-29 17:08","pubTimestamp":1669712912,"startTime":"0","endTime":"0","summary":"石药集团 (01093.HK) +0.140(+1.451%)  公布，集团开发的抗体药物偶联物CPO204的试验性新药申请(IND)已获得美国食品药品监督管理局批准，在美国开展1期、剂量递增及剂量扩展研究以评估该产品针对局部晚期或转移性泌尿道上皮癌患者的安全性、耐受性、药代动力学特性及初步疗效。集团指，临床前研究显示该产品对多种癌症均显示较好的抗肿瘤作用，极有希望在后续临床试验中展现出良好的治疗效果，将全力以赴推进美国的临床研究工作，力争该产品尽快上市。(ha/a)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229900&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false},{"id":"2287752012","title":"石药集团(01093)开发的抗体药物偶联物CPO204的试验性新药申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2287752012","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2287752012?lang=zh_CN&edition=full","pubTime":"2022-11-29 17:08","pubTimestamp":1669712896,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 公布，该集团开发的抗体药物偶联物 CPO204的试验性新药申请 已获得美国食品药品监督管理局批准，在美国开展1期、剂量递增及剂量扩展研究以评估该产品针对局部晚期或转移性泌尿道上皮癌患者的安全性、耐受性、药代动力学特性及初步疗效。该集团将全力以赴推进美国的临床研究工作，力争该产品尽快上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/838924.html","is_publish_highlight":false},{"id":"2287485695","title":"智通港股通资金流向统计(T+2)|11月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2287485695","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2287485695?lang=zh_CN&edition=full","pubTime":"2022-11-29 07:30","pubTimestamp":1669678257,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，11月24日,碧桂园、碧桂园服务、药明生物南向资金净流入金额位列市场前三，分别净流入3.37 亿、1.89 亿、7338.76 万盈富基金、腾讯控股、中远海控南向资金净流出金额位列市场前三，分别净流出-12.39 亿、-4.52 亿、-2.64 亿在净流入比方面，泉峰控股、周生生、海通国际以70.00%、68.69%、64.46%位列市场前三。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/838583.html","is_publish_highlight":false},{"id":"2286223532","title":"从10.32港元到13.52港元，围绕石药集团估值，机构的分歧点在哪？","url":"https://stock-news.laohu8.com/highlight/detail?id=2286223532","media":"界面新闻","top":-1,"share":"https://www.laohu8.com/m/news/2286223532?lang=zh_CN&edition=full","pubTime":"2022-11-28 07:20","pubTimestamp":1669591236,"startTime":"0","endTime":"0","summary":"净利润增速显著低于收入表现，是老牌制药企业石药集团今年公布的成绩单。　　最新财报显示，前三季石药集团收入234.96亿元，同比增加13.8%；归母净利润44.68亿元，同比增加3.1%。数据显示，石药集团核心抗肿瘤相关产品增速仅2.3%，逊于预估。研发方面，2022年以来公司继续对包括mRNA新冠疫苗等多条产品线持续投入，前三季研发投入达29.20亿元，同比增加16.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/chanjing/gsnews/2022-11-28/doc-imqqsmrp7783523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://finance.sina.com.cn/chanjing/gsnews/2022-11-28/doc-imqqsmrp7783523.shtml","is_publish_highlight":false},{"id":"2286834529","title":"国君研究 | 一周研选1121-1126","url":"https://stock-news.laohu8.com/highlight/detail?id=2286834529","media":"国泰君安证券研究","top":-1,"share":"https://www.laohu8.com/m/news/2286834529?lang=zh_CN&edition=full","pubTime":"2022-11-26 07:10","pubTimestamp":1669417800,"startTime":"0","endTime":"0","summary":"下周关注：中国公布1年期、5年期贷款市场报价利率；美国公布11月制造业和服务业PMI初值；欧元区、英国、日本公布11月制造业PMI；德国公布第三季度GDP总量。得益于国内消费税增速大幅上行，10月税收收入成为贡献一般公共预算收入上行的主要力量，而前期持续高增的非税收入有所回落。截至11月初，中证央企PE分位","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650452226&idx=1&sn=d64c8e480d887c4d23baf1eb1a5c68c3&chksm=886d100abf1a991c864364f455296c06ea6b11045d8c9b1e209dc9b663880506e40577cdf2c7#rd","is_publish_highlight":false},{"id":"2286357160","title":"【港股通】石药集团(01093)反复跌逾2% 遭高盛削目标价 指其肿瘤销售略微疲软","url":"https://stock-news.laohu8.com/highlight/detail?id=2286357160","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2286357160?lang=zh_CN&edition=full","pubTime":"2022-11-25 10:57","pubTimestamp":1669345021,"startTime":"0","endTime":"0","summary":"石药集团盘中股价受压走低，最新报9.59港元，跌2.04%，成交额8370.09万港元。高盛发研报指，石药集团第三季度销售收入78.9亿元，同比增长15.6%，与高盛预期79.7亿元基本持平，虽然大多数品类与市场一致，API保持强劲，市场份额增加，但肿瘤部分从第二季度的低基数连续下滑。该行对公司2022/23/24年度净利润预测进行了微调-4.4%/+2.1%/+0.6%，考虑到肿瘤销售略微疲软，目标价从10.87港元下调5%至10.32港元，评级为“买入”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=dffaf342df308275f3c43ae690596e8d","is_publish_highlight":false},{"id":"2286141354","title":"【券商聚焦】高盛削石药集团(01093)目标价5%至10.32港元 指三季度营收略降肿瘤部分疲软","url":"https://stock-news.laohu8.com/highlight/detail?id=2286141354","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2286141354?lang=zh_CN&edition=full","pubTime":"2022-11-25 10:04","pubTimestamp":1669341866,"startTime":"0","endTime":"0","summary":"高盛发布研究报告指出，石药集团第三季度销售收入78.9亿元，同比增长15.6%，与高盛预期79.7亿元基本持平，虽然大多数品类与市场一致，API保持强劲，市场份额增加，但肿瘤部分从第二季度的低基数连续下滑。虽然销货成本、销售管理和研发基本符合该行的预期，但成品药品销售略微疲软导致利润不及预期。尽管现有的肿瘤投资组合面临一些压力，但由于新冠疫苗的潜在增长，管理层指引了2022年和2023年两位数不含疫苗的销售增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=01c5bccf05b6584f551de956adbcf89c","is_publish_highlight":false},{"id":"2286359629","title":"国金证券：糖尿病及肥胖症治疗药物市场广阔 看好GLP-1RA产品未来成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2286359629","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2286359629?lang=zh_CN&edition=full","pubTime":"2022-11-25 09:14","pubTimestamp":1669338869,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研究报告称，国内糖尿病及肥胖症治疗药物市场广阔，目前GLP-1RA产品竞争格局较好且渗透率较低。国金证券主要观点如下：GLP-1RA疗效优异、安全性好，糖尿病药物中优势显著。临床试验结果显示，GLP-1RA药物还具有减轻体重、降低心血管结局风险等临床获益。自2017年以来，GLP-1RA陆续进入国家和地区医保，市场份额稳步提升。目前国内治疗肥胖症药物仅有奥利司他获批上市，患者选择范围有限。多个GLP-1RA已开始申报减重适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/837043.html","is_publish_highlight":false},{"id":"2286356037","title":"*高盛微削石药集团(01093)目标价5%至10.32港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2286356037","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2286356037?lang=zh_CN&edition=full","pubTime":"2022-11-25 08:57","pubTimestamp":1669337874,"startTime":"0","endTime":"0","summary":"高盛将石药集团(01093)目标价从10.87港元下调5%至10.32港元，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=686d78ec074f9ca58ed6a991b167244a","is_publish_highlight":false},{"id":"2286635513","title":"晨报1125 | 非银、产业、电新、望变电气、恒辉安防、石药集团、快手-W","url":"https://stock-news.laohu8.com/highlight/detail?id=2286635513","media":"国泰君安证券研究","top":-1,"share":"https://www.laohu8.com/m/news/2286635513?lang=zh_CN&edition=full","pubTime":"2022-11-25 07:10","pubTimestamp":1669331400,"startTime":"0","endTime":"0","summary":"上市险企把握客户的保本理财需求，2023年开门红加大增额终身寿等理财类产品的推动力度。2022年以来上市险企基于客户需求加大健康险产品的创新力度，提升客户的健康保障覆盖面。全球储能规模十年破10亿美元，锂电领先地位为钠电发展提振信心。全球已有近三十家企业布局钠离子电池，产业化应用涉及储能、电动车多领域。首次覆盖，给予公司“增持”评级。公司现有取向硅钢产能10万吨，2021年公司取向硅钢产量位居国内民营企业第一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650452192&idx=1&sn=ad1dca427827755cb42a87b4c924a45e&chksm=886d11e8bf1a98fe4713767c000262d4b8d9a519944945bfe2b587246e2ee28ce1ef294634b4#rd","is_publish_highlight":false},{"id":"2285042388","title":"国泰君安：维持石药集团(01093)“增持”评级 目标价升至11.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2285042388","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2285042388?lang=zh_CN&edition=full","pubTime":"2022-11-24 16:31","pubTimestamp":1669278714,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国泰君安发布研究报告称，维持石药集团“增持”评级，预测2022-24年EPS为0.51/0.57/0.64元，目标价上调至11.8港元。报告中称，石药集团多数产品商业放量符合预期，预计整体将维持平稳较快增长。成药业务收入186.13亿元，同比增加10.8%，其中产品销售184.27亿元，授权费收入1.86亿元。神经系统用药收入60.1亿元，同比增长9.2%，预计主要因恩必普成功实现以量补价，后续TNK铭复乐有望与恩必普发挥协同效应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/836666.html","is_publish_highlight":false},{"id":"2285809437","title":"【券商聚焦】招证国际维持石药集团(01093)“增持”评级 指有望验证mRNA平台实力","url":"https://stock-news.laohu8.com/highlight/detail?id=2285809437","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2285809437?lang=zh_CN&edition=full","pubTime":"2022-11-24 15:34","pubTimestamp":1669275290,"startTime":"0","endTime":"0","summary":"招证国际发布研究报告指出，石药集团22年三季度经调整净利润同比增长16.4％，符合该行预期，肿瘤产品销售仍表现疲软，同比增长2％；公司指引1）23财年收入端双位数增长，2）恩必普的国谈降价风险可拉，3）新冠mRNA疫苗项目进展正常。该行认为上述努力和潜在进展有望进一步验证公司mRNA平台的实力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=19bdde77667e0aa97a4dc25f15117aef","is_publish_highlight":false},{"id":"2285180307","title":"中金：石药(01093.HK)第三季业绩符预期  静待mRNA疫苗进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2285180307","media":"AAFN","top":-1,"share":"https://www.laohu8.com/m/news/2285180307?lang=zh_CN&edition=full","pubTime":"2022-11-24 14:02","pubTimestamp":1669269771,"startTime":"0","endTime":"0","summary":"中金发表报告指，石药  第三季业绩符合预期。此外管理层维持全年业绩指引，并预计明年收入、净利润和研发费用均将有双位数增长，好于市场预期。报告指，静待石药mRNA疫苗进展，目前mRNA疫苗完成2期临床，数据已提交紧急使用申请。此外公司也在部分海外国家组织Ⅲ期序贯免疫试验。公司表示另有两款小分子处于临床前研发阶段，分别是用于重症患者清除炎症因子的JAK抑制剂和用于轻中度患者的抗病毒分子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1228787&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false},{"id":"2285208872","title":"中金：维持石药集团跑赢行业评级 目标价11.3港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2285208872","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2285208872?lang=zh_CN&edition=full","pubTime":"2022-11-24 11:50","pubTimestamp":1669261812,"startTime":"0","endTime":"0","summary":"中金发布研究报告称，维持石药集团“跑赢行业”评级，核心盈利预测不变，目标价11.3港元，较当前股价有18.1%的上行空间。公司1-3Q21收入235亿元，归母净利润45亿元，同比+3%；扣非净利润46亿元，同比+15%，业绩符合预期。此外管理层维持2022年业绩指引，并预计23年收入、净利润和研发费用均将有双位数增长，好于市场预期。　　报告中称，公司预计今年底恩必普医保续约将会较为平稳。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2022-11-24/doc-imqmmthc5807825.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2022-11-24/doc-imqmmthc5807825.shtml","is_publish_highlight":false},{"id":"2285722348","title":"【券商聚焦】大和维持石药集团(01093)“买入”评级 指三季度NBP和抗感染药提高收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2285722348","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2285722348?lang=zh_CN&edition=full","pubTime":"2022-11-24 11:36","pubTimestamp":1669260969,"startTime":"0","endTime":"0","summary":"大和发布研究报告指出，石药集团22年第三季度营收同比增长16%，至78.85亿元，较市场普遍预期高出2%；净利润同比增长18%至15.02亿元，比市场普遍预期高出5%。成品药品部分恢复了同比13%的收入增长，神经系统药物和抗感染药物是主要增长动力。该行将公司2022-23年收益预测降低1-2%，目标价12.80港元，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=73db01e27fa77ebd92903ad311fb6654","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0439},{"period":"1month","weight":0.2379},{"period":"3month","weight":0.2585},{"period":"6month","weight":0.3527},{"period":"1year","weight":0.2681},{"period":"ytd","weight":0.2097}],"websiteUrl":"http://www.cspc.com.hk","compareEarnings":[{"period":"1week","weight":0.0613},{"period":"1month","weight":0.2662},{"period":"3month","weight":-0.051},{"period":"6month","weight":-0.1179},{"period":"1year","weight":-0.2078},{"period":"ytd","weight":-0.2052}],"name":"石药集团","description":"石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门：成药部门、抗生素（中间体及原料药）部门、维生素C（原料药）部门及咖啡因及其他（原料药）部门，分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.535714,"avgChangeRate":0.012935},{"month":2,"riseRate":0.75,"avgChangeRate":0.104475},{"month":3,"riseRate":0.464286,"avgChangeRate":0.024031},{"month":4,"riseRate":0.571429,"avgChangeRate":0.056961},{"month":5,"riseRate":0.607143,"avgChangeRate":0.045162},{"month":6,"riseRate":0.321429,"avgChangeRate":0.006761},{"month":7,"riseRate":0.37931,"avgChangeRate":0.004432},{"month":8,"riseRate":0.448276,"avgChangeRate":0.019201},{"month":9,"riseRate":0.517241,"avgChangeRate":-0.006033},{"month":10,"riseRate":0.586207,"avgChangeRate":0.011883},{"month":11,"riseRate":0.448276,"avgChangeRate":0.008663},{"month":12,"riseRate":0.5,"avgChangeRate":-0.01028}],"exchange":"SEHK","nameEN":"CSPC PHARMA","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.10.5","shortVersion":"4.10.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情"}}